| Literature DB >> 35743445 |
Bianka Heiling1,2, Leonie I E E Wiedfeld1, Nicolle Müller3, Niklas J Kobler1, Alexander Grimm4, Christof Kloos3, Hubertus Axer1.
Abstract
In diabetic patients, controversies still exist about the validity of electrodiagnostic and nerve ultrasound diagnosis for carpal tunnel syndrome (CTS). We analyzed 69 patients with type 2 diabetes. Nerve conduction studies and peripheral nerve ultrasound of the median nerve over the carpal tunnel were performed. CTS symptoms were assessed using the Boston Carpal Tunnel Questionnaire. Polyneuropathy was assessed using the Neuropathy Symptom Score and the Neuropathy Disability Score. Although 19 patients reported predominantly mild CTS symptoms, 37 patients met the electrophysiological diagnosis criteria for CTS, and six patients were classified as severe or extremely severe. The sonographic cross-sectional area (CSA) of the median nerve at the wrist was larger than 12 mm2 in 45 patients (65.2%), and the wrist-to-forearm-ratio was larger than 1.4 in 61 patients (88.4%). Receiver operating characteristic analysis showed that neither the distal motor latency, the median nerve CSA, nor the wrist-to-forearm-ratio could distinguish between patients with and without CTS symptoms. Diagnosis of CTS in diabetic patients should primarily be based upon typical clinical symptoms and signs. Results of electrodiagnostic testing and nerve ultrasound have to be interpreted with caution and additional factors have to be considered especially polyneuropathy, but also body mass index and hyperglycemia.Entities:
Keywords: carpal tunnel syndrome; diabetes mellitus; nerve conduction study; peripheral nerve ultrasound
Year: 2022 PMID: 35743445 PMCID: PMC9225449 DOI: 10.3390/jcm11123374
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure 1Nerve conduction studies and peripheral nerve ultrasound of the median nerve at the wrist. (A) Placement of electrodes. (B) Motor nerve conduction study. (C) Sensory nerve conduction study. (D) Normal cross-sectional area (CSA) of the median nerve. (E) Increased CSA of the median nerve. Abbreviations: CMAP, compound motor action potential; CSA, cross-sectional area; DML, distal motor latency; SNAP, sensory nerve action potential.
Baseline characteristics of the patients (n = 69), categorical variables.
| Variable | n | % | |
|---|---|---|---|
| Sex | Female | 26 | 37.7 |
| Male | 43 | 62.3 | |
| BCTQ SSS | 0 | 50 | 72.5 |
| 1 | 17 | 24.6 | |
| 2 | 1 | 1.4 | |
| 3 | 1 | 1.4 | |
| BCTQ SSS right hand | 0 | 50 | 72.5 |
| 1 | 17 | 24.6 | |
| 2 | 1 | 1.4 | |
| 3 | 1 | 1.4 | |
| BCTQ SSS left hand | 0 | 51 | 73.9 |
| 1 | 16 | 23.2 | |
| 2 | 1 | 1.4 | |
| 3 | 1 | 1.4 | |
| BCTQ FSS | 0 | 50 | 72.5 |
| 1 | 18 | 26.1 | |
| 4 | 1 | 1.4 | |
| Polyneuropathy | Yes | 49 | 71.0 |
| No | 20 | 29.0 | |
| NSS | No symptoms (0–2) | 27 | 39.1 |
| Mild symptoms (3–4) | 10 | 14.5 | |
| Moderate symptoms (5–6) | 16 | 23.2 | |
| Severe symptoms (7–10) | 17 | 24.6 | |
| NDS | No deficits (0–2) | 9 | 13.2 |
| Mild deficits (3–5) | 18 | 26.5 | |
| Moderate deficits (6–8) | 26 | 38.2 | |
| Severe deficits (9–10) | 15 | 22.1 | |
| CTS symptoms | Asymptomatic + no neuropathy | 18 | 26.1 |
| CTS symptoms only | 2 | 0.3 | |
| Diabetic neuropathy only | 32 | 46.4 | |
| CTS symptoms and neuropathy | 17 | 24.6 |
Abbreviations: BCTQ, Boston Carpal Tunnel Questionnaire; FSS, Functional Status Scale; NDS, Neuropathy Disability Score; NSS, Neuropathy Symptom Score; SSS, Symptom Severity Scale.
Baseline characteristics of the patients (n = 69), metric variables.
| Variable | Mean | SD | Minimum | Maximum |
|---|---|---|---|---|
| Age (years) | 66.77 | 9.72 | 44 | 82 |
| Duration of diabetes (years) | 14.72 | 8.95 | 0.63 | 38 |
| Body mass index (kg/m2) | 32.42 | 6.17 | 20.1 | 48.0 |
| HbA1c (mmol/mol) | 59.08 | 10.94 | 27.98 | 82.51 |
| Glomerular filtration rate (mL/min) | 71.79 | 20.64 | 27.92 | 107.25 |
| CSA median nerve at wrist (mm2) | 13.53 | 4.74 | 5.00 | 37.00 |
| CSA median nerve at forearm (mm2) | 7.03 | 2.09 | 4.00 | 15.00 |
| Wrist-to-forearm-ratio | 2.05 | 0.76 | 0.33 | 4.75 |
| Distal motor latency median nerve (ms) | 4.42 | 0.67 | 3.50 | 6.15 |
| CMAP amplitude median nerve (mV) | 10.12 | 4.39 | 0 | 22.30 |
| Sensory nerve CV median nerve (m/s) | 43.26 | 7.84 | 29.0 | 63.6 |
| SNAP amplitude median nerve (µV) | 13.31 | 9.64 | 0 | 48.9 |
| NSS (0–10 points) | 3.84 | 3.23 | 0 | 9 |
| NDS (0–10 points) | 6.10 | 2.75 | 0 | 10 |
Abbreviations: CMAP, compound motor action potential; CSA, cross-sectional area; CV, conduction velocity; NDS, Neuropathy Disability Score; NSS, Neuropathy Symptom Score; SNAP, sensory nerve action potential.
Figure 2Nerve conduction studies of the median nerve. (A) Scatter plot of sensory nerve conduction velocity and distal motor latency. (B) Histogram of distal motor latencies. (C) Box plots of distal motor latencies in patients with and without CTS symptoms. (D) Box plots of distal motor latencies in patients with and without diabetic polyneuropathy.
Figure 3Peripheral nerve ultrasound measurements of the median nerve at the wrist. (A) Histogram of the CSA at the wrist. (B) Histogram of the wrist-to-forearm-ratio. (C) Box plots of median nerve CSA at the wrist in patients with and without CTS symptoms and patients with and without diabetic polyneuropathy. (D) Box plots of wrist-to-forearm-ratio in patients with and without CTS symptoms and patients with and without diabetic polyneuropathy.
Figure 4Scatterplots of distal motor latencies and peripheral nerve ultrasound measurements. (A) Distal motor latencies and median nerve CSA at the wrist. (B) Distal motor latencies and wrist-to-forearm-ratio.
Linear regression.
| Variable | Coefficient | Standard Error |
| Beta |
|---|---|---|---|---|
|
| ||||
| Constant | 7.269 | 8.375 | 0.027 | |
| Body mass index | 0.197 | 0.102 | 0.047 | 0.255 |
|
| ||||
| Constant | 1.036 | 3.206 | 0.052 | |
| HbA1c | 0.018 | 0.097 | 0.043 | 0.260 |
Figure 5ROC curve analysis shows that DML, median nerve CSA at the wrist, and wrist-to-forearm-ratio were not suited to distinguish between diabetic patients with and without symptoms for CTS.